EI 012
Alternative Names: EI-012Latest Information Update: 01 Sep 2021
Price :
$50 *
At a glance
- Originator Elixiron Immunotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 18 Aug 2021 Early research in Cancer in China (Parenteral) (Elixiron Immunotherapeutics pipeline, August 2021)